Related Experiment Videos
Calcium entry blockers in the treatment of hypertension. Current status and future prospects
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-8852.
Insights
Calcium entry blockers are vital for hypertension treatment. Newer generations offer targeted vasodilation with fewer side effects, potentially benefiting heart failure patients and improving renal function.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Calcium entry blockers are increasingly utilized for hypertension management.
- Existing agents show similar efficacy but vary in cardiac and vascular effects.
- Newer dihydropyridine calcium entry blockers offer improved specificity.
Purpose of the Study:
- To review the current and emerging roles of calcium entry blockers in hypertension.
- To compare the distinct pharmacological profiles of different calcium entry blocker generations.
- To discuss implications for specific patient populations and co-therapies.
Main Methods:
- Literature review of clinical trials and pharmacological studies.
- Comparative analysis of antihypertensive efficacy and side effect profiles.
- Evaluation of effects on renal function and potential for cardioprotection.
Main Results:
- Current calcium entry blockers are effective antihypertensives with varied nodal and vascular actions.
- Next-generation dihydropyridines demonstrate enhanced vasodilation and reduced negative inotropic effects.
- Drug response is largely independent of race and age; mild natriuresis may reduce need for sodium restriction/diuretics.
- Short-term use preserves renal function; long-term effects and coronary protection remain under investigation.
Conclusions:
- Calcium entry blockers are essential antihypertensive agents.
- Second-generation drugs offer pharmacologic advantages, potentially benefiting specific patient groups.
- Further research is needed on long-term renal effects and cardioprotective potential.
Abstract:
Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.